医学临床研究
  2025年7月20日 星期日           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2020, Vol. 37 Issue (8): 1139-1141    DOI: 10.3969/j.issn.1671-7171.2020.08.006
  论著 本期目录 | 过刊浏览 | 高级检索 |
右丙亚胺联合左卡尼汀预防表柔比星化疗致肝癌患者心脏毒性的效果
苏妍
滨州医学院烟台附属医院,山东 烟台 264100
Effect of Dextroimide Combined with Levocarnitine on the Prevention of Cardiac Toxicity Induced by Epirubicin Chemotherapy in Patients with Hepatocellular Carcinoma
SU Yan
Yantai Affiliated Hospital of Binzhou Medical College, Shandong Yantai 264100
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的】 探讨右丙亚胺联合左卡尼汀用于表柔比星致肝癌患者心脏毒性的疗效及安全性。【方法】 在本院接受表柔比星化疗的86例肝癌患者随机分为两组,各43例。两组患者入院后均给予表柔比星化疗,在化疗前一天,对照组给予右丙亚胺注射液治疗,观察组给予右丙亚胺和左卡尼汀治疗,两组患者均常规给予5个周期的辅助化疗,3周为1个周期。观察两组心电图指标(窦速、早搏、QRS低电压、ST-T改变、Q-T间期延长、房室传导阻滞)以及心肌酶谱标志物的变化。比较两组疗效及治疗期间非心脏毒性不良反应发生率。【结果】 ①治疗后两组心电图异常发生率随着化疗周期数的增加而上升,对照组治疗后心电图异常发生率均高于治疗前(P<0.05),观察组治疗后心电图异常发生率较治疗前虽增加,但差异无显著性(P>0.05),但明显低于对照组(P<0.05);②观察组的心肌酶谱标志物水平治疗后较治疗前无显著升高(P>0.05),对照组较治疗前升高(P<0.05),且明显高于观察组(P<0.05);③两组患者治疗期间非心脏毒性不良反应发生率比较差异无显著性(P>0.05)。【结论】 右丙亚胺联合左卡尼汀较单一应用右丙亚胺对表柔比星所致心脏毒性的发生具有更好的防护作用,且安全性较好。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
苏妍
关键词 肝肿瘤/治疗肉碱/药理学抗肿瘤药/药理学    
Abstract:【Objective】 To study the efficacy and safety of dextroimide combined with levocarnitine for epirubicin-induced cardiotoxicity in patients with hepatocellular carcinoma. 【Methods】 A total of 86 patients with liver cancer received epirubicin chemotherapy in our hospital were selected as study subjects. The patients were randomly divided into two groups with 43 cases in each group. The patients in both groups were treated with epirubicin after admission. One day before chemotherapy, patients in the control group received dexamine injection, while patients in the observation group received both dextromine and levocarnitine. Patients in both groups were routinely given 5 cycles of adjuvant chemotherapy, with 3 weeks as a cycle. The changes of electrocardiogram (sinus tachycardia, premature beat, QRS low voltage, ST-T change, Q-T interval prolongation, atrioventricular block) and myocardial enzyme spectrum markers (LDH,cTnI,CK and CK-MB) were observed. The therapeutic effect and the incidence of non-cardiac toxicity were compared between the two groups as well. 【Results】 ①After treatment, the incidence of abnormal ECG in the two groups increased with the increase of the number of chemotherapy cycles. The incidence of abnormal ECG in the control group after treatment was higher than that before treatment (P<0.05). The incidence of abnormal electrocardiogram in the observation group was higher than that before treatment, however, the difference was not statistically significant (P<0.05). ②The level of myocardial enzyme spectrum in the observation group was not significantly increased after treatment, while the myocardial enzyme level of the control group after treatment was higher than that before treatment; and the difference was significant compared with that of the observation group (P<0.05). ③There was no statistically significant in the incidence of non-cardiac toxicity in both groups during the treatment (P>0.05). 【Conclusion】 Dextroimide combined with levocarnitine has a better protective effect on the occurrence of cardiac toxicity induced by epirubicin than single application of dextroimide.
Key wordsLiver Neoplasms/TH    Carnitine /PD    Antineoplastic Agents/PD
收稿日期: 2019-01-11     
PACS:  R735.7  
基金资助:山东省自然科学基金项目(编号:ZR2013HL001)
引用本文:   
苏妍. 右丙亚胺联合左卡尼汀预防表柔比星化疗致肝癌患者心脏毒性的效果[J]. 医学临床研究, 2020, 37(8): 1139-1141.
SU Yan. Effect of Dextroimide Combined with Levocarnitine on the Prevention of Cardiac Toxicity Induced by Epirubicin Chemotherapy in Patients with Hepatocellular Carcinoma. JOURNAL OF CLINICAL RESEARCH, 2020, 37(8): 1139-1141.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2020.08.006     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2020/V37/I8/1139
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn